Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan®-MGB probe genotyping method

  • Authors:
    • Peijia Liu
    • Hongyan Liang
    • Li Xue
    • Chun Yang
    • Yang Liu
    • Kun Zhou
    • Xiaofeng Jiang
  • View Affiliations

  • Published online on: May 2, 2012     https://doi.org/10.3892/etm.2012.566
  • Pages: 109-112
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Despite the improved ability to detect mutations in recent years, tissue specimens cannot always be procured in a clinical setting, particularly from patients with recurrence of tumors or metastasis. Therefore, the aim of this study was to investigate whether plasma is able to be used for mutation analysis instead of tissue specimens. We collected plasma from 62 patients with colorectal cancer (CRC) prior to treatment. DNA extracted from plasma and matched tumor tissues were obtained. Mutations in KRAS were amplified from the tissue specimens and sequenced by regular polymerase chain reaction (PCR) and co-amplification at lower denaturation temperature (COLD)-PCR. Plasma KRAS gene mutation on codon 12 (GGT>GAT) was detected using a nested COLD-PCR/TaqMan®-MGB probe. Mutations in plasma and matched tumors were compared. KRAS mutation on codon 12 (GGT>GAT) was found in 13 (21.0%) plasma specimens and 12 (19.4%) matched tumor tissues. The consistency of KRAS mutations between plasma and tumors was 75% (9/12), which indicated a high correlation between the mutations detected in plasma DNA and the mutations detected in the corresponding tumor DNA (P<0.001; correlation index, k=0.649). Notably, four (6.5%) patients with plasma DNA mutations had no detectable KRAS mutations in the corresponding primary tumors, and three (4.8%) patients with tumor DNA mutations had no detectable KRAS mutations in the corresponding plasma DNA samples. Thus, KRAS mutations in plasma DNA correlate with the mutation status in matched tumor tissues of patients with CRC. Our study provides evidence to suggest that plasma DNA may be used as a potential medium for KRAS mutation analysis in CRC using the COLD-PCR/TaqMan-MGB probe method.
View Figures
View References

Related Articles

Journal Cover

July 2012
Volume 4 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu P, Liang H, Xue L, Yang C, Liu Y, Zhou K and Jiang X: Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan®-MGB probe genotyping method. Exp Ther Med 4: 109-112, 2012
APA
Liu, P., Liang, H., Xue, L., Yang, C., Liu, Y., Zhou, K., & Jiang, X. (2012). Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan®-MGB probe genotyping method. Experimental and Therapeutic Medicine, 4, 109-112. https://doi.org/10.3892/etm.2012.566
MLA
Liu, P., Liang, H., Xue, L., Yang, C., Liu, Y., Zhou, K., Jiang, X."Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan®-MGB probe genotyping method". Experimental and Therapeutic Medicine 4.1 (2012): 109-112.
Chicago
Liu, P., Liang, H., Xue, L., Yang, C., Liu, Y., Zhou, K., Jiang, X."Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan®-MGB probe genotyping method". Experimental and Therapeutic Medicine 4, no. 1 (2012): 109-112. https://doi.org/10.3892/etm.2012.566